Top Health Tech Companies in Miami, FL (149)

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Market Expansion: Reach is described as nationwide, with thousands of imaging partners and access extended through employer and health‑plan channels to a large member base. This breadth indicates rapid scaling from an early-stage footprint.

Investor Backing & Capital Strength: Capital raises include a sizable Series A led by established investors, signaling confidence in continued scaling. Funding momentum accompanies ongoing hiring and expanded employer and health‑plan integrations.

Strong Revenue Growth: Investor commentary cites revenue increasing more than tenfold since an earlier investment, alongside company claims of very rapid growth. Together these signals point to accelerating topline momentum, even as precise figures remain undisclosed.

Investor Backing & Capital Strength: The company closed a $72 million Series C in 2024, bringing total funding to about $100 million to support expansion and technology investment. This capital base underwrites multi-state rollout and continued clinician hiring.

Market Expansion: Announcements detail entry into many additional states with a goal of being live in more than twenty by mid-2025. In-network arrangements with major health plans are cited as enabling broad access across much of the U.S.

Innovation-Driven Growth: The model emphasizes rigorous therapist matching, measurement-based care, and new AI investments to enhance care and reduce administrative burden. The launch of psychiatry broadens capabilities and supports scaling an integrated, tech-enabled service.

Strong Revenue Growth: Revenue is described as rising across recent years and quarters, supported by new long‑term contracts, acquisitions, and expanding client deployments. Technology‑enabled offerings and growing demand for outsourced RCM are cited as tailwinds.

Strong Market Position & Advantage: The company is presented as a category leader with an extensive client base that includes a large share of top U.S. health systems and repeated top rankings in ambulatory services. Its end‑to‑end platform and scale are highlighted as differentiators.

Investor Backing & Capital Strength: An $8.9B take‑private by TowerBrook and CD&R is framed as providing resources for innovation and expansion. The transaction is described as validating market standing and future growth potential.

Investor Backing & Capital Strength: The company reports more than $200 million raised, including a widely reported $180 million financing led by Oaktree in 2021–2022. This capital base is cited as enabling continued product development and distribution expansion.

Product Line Growth: Launch of Autopilot in March 2025 with subsequent features like Autopilot Voice, along with assets such as Pivot Health and TrustRx, indicate ongoing expansion across distribution tech and pharmacy‑adjacent services. These moves reflect a strategy to broaden the product portfolio beyond a lead‑gen marketplace.

Innovation-Driven Growth: Autopilot is positioned as an AI‑driven enrollment acquisition platform—described as an industry first—with AI‑assisted matching, pricing, and compliant consent flows. This innovation focus aims to differentiate lead generation and distribution technology.

Market Expansion: Announcements detail acquisitions and a drumbeat of new hospitals, emergency departments, and clinics across multiple states, extending Mercy’s reach in core markets. Activity includes reopening sites and adding specialty capacity, pointing to continued geographic and service growth.

Strategic Partnerships: Multi‑year affiliations with the Alice L. Walton Foundation/Heartland Whole Health Institute (with Cleveland Clinic collaboration) and a 10‑year data alliance with Mayo Clinic are positioned to expand specialty access and enable data‑driven care at scale. These long‑horizon collaborations signal durable external support for growth initiatives.

Profitability: Recent system updates note a return to operating gains in FY2024 and improvement through parts of FY2026, providing a base to fund expansion. Reported rebounds following earlier losses indicate improving financial stability.

Strong Market Position & Advantage: Humana is a top-tier player in Medicare Advantage with substantial local dominance across many counties and an integrated senior-care platform via CenterWell. Its scale in MA and senior-focused delivery underpins leadership in its core segment.

Strong Revenue Growth: Revenue has been rising, with year-over-year increases and higher 2025 guidance. Momentum is supported by CenterWell contributions and higher prescription volumes.

Future-Ready Strategy: Management is pruning low-margin geographies, repricing benefits, and concentrating on government programs and CenterWell to strengthen long-term earnings quality. Product and footprint adjustments for 2026, alongside early signs of star-rating stabilization, point to a rebuild path.

Strong Market Position & Advantage: Strong Market Position & Advantage: Datavant is positioned as a leading, large-scale health data exchange/connectivity platform, with broad penetration across major healthcare stakeholders and high-volume record movement anchored by the Ciox merger.

Market Expansion: Market Expansion: The company is expanding into additional end-markets (including legal/insurance) and extending its footprint through acquisitions such as Ontellus, alongside continued ecosystem build-out across providers, payers, and life sciences.

Product Line Growth: Product Line Growth: The portfolio is widening beyond connectivity and retrieval into real-world evidence analytics and AI-enabled record structuring via acquisitions like Aetion and DigitalOwl, plus platform launches such as clean-room-based collaboration offerings.

Strong Market Position & Advantage: Scale indicators such as preparing more than 2,000 team members to support 6.4 million Medicare members for AEP 2026, working with 7 of the top 20 health plans, and processing 2.2+ billion annual transactions point to an entrenched footprint in its niches. This presence aligns with a credible leadership stance in Medicare-focused operations and supplemental benefits.

Investor Backing & Capital Strength: TPG’s 2022 take-private at roughly $1.1B underscores access to capital and ongoing investment capacity. Subsequent product development and portfolio moves (e.g., Pareto’s StarIQ launch and the earlier HealthSmart acquisition) are consistent with continued funding of growth initiatives.

Strategic Partnerships: The 2026 Sagility Synchrony alliance with Sagility and Simplify Healthcare integrates Miramar into a broader managed-services model, indicating expanded go-to-market reach. Such collaborations can amplify pipeline and adoption within Medicare operations.